Fred B. Davenport, Former PPD, Inc. (PPDI) President, Joins Clinipace Worldwide Board Of Directors

Clinipace Worldwide a global, digital clinical research organization (dCRO), today announced the addition of industry veteran Fred B. Davenport, Jr., to its Board of Directors.

As an independent director, Fred brings to Clinipace a significant pedigree in scaling global organizations within the CRO industry, having spent 10 years at Pharmaceutical Product Development, Inc. (PPD) during its rapid growth phase, followed by 6 years on the Board of Directors for Medpace, Inc. At PPD, Fred served in various roles, including General Counsel, Executive Vice President, and President.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.